Form D · Biotechnology
Avery Therapeutics, Inc.
Tucson, AZ · CIK 0001708135
Offering snapshot reported Sep 21, 2026 · SEC filing
- Reported sold
- $8.47M Offering amount: $15.4M
- Investors reported
- 23 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 19, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 21, 2026 | Initial | $8,468,859 | No comparison | 23 | SEC filing |
| Jun 1, 2017 | Initial | $500,000 | No comparison | 16 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-598273
Source: Form D, filed Sep 21, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Steven Goldman | Executive |
| Jennifer Koevary | Executive |
| Jordan Lancaster | Director, Executive |
| Lawrence Mehren | Director |
| Emile Nuwaysir | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2500 N. Tucson Blvd. Ste. 140
Tucson, AZ, 85716
Phone: 520-977-4980
Tucson, AZ, 85716
Phone: 520-977-4980